PALISADE BIO, INC.
Palisade Bio (PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis, with topline results expected in Q4 2027. The trial plans to enroll ~204 patients and test the oral drug PALI-2108. A positive result would be a significant catalyst for the company, according to the company.
Analysts maintained Buy ratings on Relay Therapeutics (RLAY), Boston Scientific (BSX), and Palisade Bio (PALI). Price targets set at $25 for RLAY, $66 for BSX, and $7 for PALI. All three have Strong Buy consensus ratings.
Oppenheimer reiterated an Outperform rating and $8.00 price target on Palisade Bio (NASDAQ:PALI) after additional data from UEG Week. The stock is down 49% over six months but has a Strong Buy consensus and targets ranging from $5 to $25. New tissue analyses showed reduced PDE4D expression and signs of tissue remodeling. Phase 2 trials are ongoing, with data expected in 2H27. Other analysts also reiterated or initiated positive ratings.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning PALI (PALISADE BIO, INC.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent PALI coverage spans financial news, technology and insider activity.
In the last 30 days, PALI insiders filed 2 SEC Form 4 transactions — 2 purchases ($29K) and no sales. The most active reporter was Williams Donald Allen with 2 filings.
The start of a pivotal Phase 2b trial is a positive catalyst that could lift the stock if early data are encouraging.
Buy rating reaffirmed with a new price target.
Positive early‑stage trial data suggest potential efficacy, likely supporting upside pressure on the stock.
Positive early-phase data may boost investor sentiment and drive short-term upside.
Positive clinical data and higher price target suggest upside potential.
AlphAI scores every news story that mentions PALI with an AI model for sentiment and relevance, and aggregates insider trades from PALISADE BIO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Palisade Bio (PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis, with topline results expected in Q4 2027. The trial plans to enroll ~204 patients and test the oral drug PALI-2108. A positive result would be a significant catalyst for the company, according to the company.
1 min readAnalysts maintained Buy ratings on Relay Therapeutics (RLAY), Boston Scientific (BSX), and Palisade Bio (PALI). Price targets set at $25 for RLAY, $66 for BSX, and $7 for PALI. All three have Strong Buy consensus ratings.
2 min readOppenheimer reiterated an Outperform rating and $8.00 price target on Palisade Bio (NASDAQ:PALI) after additional data from UEG Week. The stock is down 49% over six months but has a Strong Buy consensus and targets ranging from $5 to $25. New tissue analyses showed reduced PDE4D expression and signs of tissue remodeling. Phase 2 trials are ongoing, with data expected in 2H27. Other analysts also reiterated or initiated positive ratings.
2 min readPalisade Bio (PALI) reported that its experimental drug PALI-2108 showed a 58.8% reduction in a gut inflammation marker in five Crohn's disease patients after 14 days. The Phase 1b study also demonstrated endoscopic improvement and reduced intestinal inflammation. The company is advancing Phase 2b studies for ulcerative colitis and initiating a Phase 2a study for Crohn's disease.
2 min readHC Wainwright & Co. maintained a Buy rating on Palisade Bio, setting a $7 price target, implying a 340.3% upside from the Oct 12 close of $1.59. The firm cited promising clinical data for PALI-2108, showing 40% endoscopic response in 14 days, and a favorable safety profile.
1 min readPalisade Bio (PALI) presented new data on PALI-2108 at ACG 2026, showing targeted intestinal exposure and early clinical activity. The data supports ongoing Phase 2 trials for ulcerative colitis and Crohn's disease. Two abstracts received ACG Presidential Poster Awards.
1 min readPalisade Bio presented clinical findings at the ACG 2026 Annual Meeting. PALI-2108 showed early clinical activity in UC and Crohn's patients, with mean score reductions of 62.8% and 47.5% respectively. The company is advancing Phase 2 trials for both indications. According to the company, the findings support the drug's mechanism and delivery platform.
2 min readRaymond James initiated coverage on Palisade Bio (NASDAQ:PALI) with an Outperform rating and $6.00 price target. The biotech company is developing PALI-2108 for inflammatory bowel disease. Analyst Thomas Deal cited compelling risk/reward ahead of Phase 2 data updates in 2027. The stock trades at $1.45, with high volatility (beta 1.62) and a strong balance sheet.
2 min readWilliams Donald Allen purchased 20,000 shares of PALISADE BIO, INC. (PALI) at an average of $1.44 ($1.42–$1.46) across 2 trades over 2026-10-01 to 2026-10-02.
1 min readPalisade Bio (PALI) CEO John David Finley gifted 176,800 shares of common stock on August 19, 2026, transferring 88,400 shares to FCW Investments, LLC, which he manages. Post-transaction, he directly holds 129,288 shares and indirectly holds 88,451 shares. The transactions were not under a Rule 10b5-1 trading plan.
1 min read
